 |
A Chat with AnatAuthor: ApotheCom
"A Chat with Anat" is a series for ophthalmologists who are interested in improving delivery of care for patients living with retinal disease, and for those interested in clinically-challenging situations or controversies in care. Im Professor Anat Loewenstein, Chair of the Department of Ophthalmology at Tel Aviv Sourasky Medical Centre in Israel, and Professor of Ophthalmology and Vice Dean at Tel Aviv University. For each episode, I will be joined by internationally renowned colleagues to discuss these important topics. This podcast series is sponsored and organized by Bayer and produced by ApotheCom.This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise. This is not intended for UK audiences. Language: en-gb Genres: Life Sciences, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
New options for an old disease: Treatment of CSC
Tuesday, 27 January, 2026
In this episode, I am joined by my fellow Vision Academy member Professor Sobha Sivaprasad, Professor of Retinal Clinical Studies at the UCL Institute of Ophthalmology and Consultant Ophthalmologist at Moorfields Eye Hospital in the United Kingdom. Join us as we discuss key aspects of the diagnosis and treatment of central serous chorioretinopathy (CSC). In this episode, we summarize published evidence for the treatment of CSC, and use the guidance developed by the Vision Academy to discuss practical disease management and treatment of phenotypic variations. We also dive into cases we have treated in our own clinics, and explore how access to treatment can vary between clinics and countries. To learn more about the diagnosis and treatment of CSC, read the Vision Academy Viewpoint and publication. For more information about patient-focused care, visit the nAMD Barometer and DR Barometer websites. If you enjoyed this episode, SUBSCRIBE to “A Chat with Anat” to make sure you never miss an episode! Speaker disclosures: Professor Anat Loewenstein Consultant: 4DMT, Abbvie, Astellas, Aviceda, Bayer, Beyeonics, Boehringer Ingelheim; Eyepoint, NotalVision, Ocular Therapeutix, Oculis, Ocuphire, Opthea, Roche, and Voiant. Professor Sobha Sivaprasad Received funding/fees from AbbVie, Alimera Sciences, Amgen, Apellis, Astellas, Bayer, Biogen, Boehringer Ingelheim, Clearside Biomedical, EyeBio, EyePoint, Iveric Bio, Janssen, Kriya Therapeutics, Novo Nordisk, Ocular Therapeutix, OcuTerra, Optos, Ripple Therapeutics, Roche, Sanofi and Stealth BioTherapeutics, and is Editor in Chief of Eye. January 2026 | PP-PF-OPHT-ALL-0262-1This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing. This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program. The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.
